Article
BRCA1 alterations with additional defects in DNA damage response genes may confer chemoresistance to BRCA-like breast cancers treated with neoadjuvant chemotherapy.
Genes, chromosomes & cancer - 1 May 2017
Takada Mamoru, Nagai Shigenori, Haruta Masayuki, Sugino Ryuichi P, Tozuka Katsunori, Takei Hiroyuki, Ohkubo Fumie, Inoue Kenichi, Kurosumi Masafumi, Miyazaki Masaru, Sato-Otsubo Aiko, Sato Yusuke, Ogawa Seishi, Kaneko Yasuhiko
Abstract excerpt
The BRCA-like phenotype is a feature that some sporadic breast cancers share with those occurring in BRCA1 or BRCA2 mutation carriers. As tumors with the phenotype have defects in the DNA damage response pathway, which may increase sensitivity to drugs such as DNA cross-linking agents and PARP inhibitors, a method to identify this phenotype is important. The prediction of chemoresistance, which frequently...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.